Home Care Medication Management Program for the Frail Elderly
The purpose of this study is to determine whether a home care medication management program which includes nurse coordination and use of the MD.2 medication-dispensing machine will affect older adults' health outcomes, satisfaction, use of health care services, and health care costs over a one year period. The investigators propose a longitudinal three group repeated measures design, enrolling, and randomly assigning, clients who are discharged from a home health care agency with documented problems in medication management. One group will receive the MD.2 medication dispensing device and nurse coordination, the second group will receive a Medplanner: a simple box that has separate compartments for individual medication times over the course of a week plus nurse coordination, and the final group will receive Usual Care.
The study hypotheses are the following:
H1: With respect to health status outcomes, the MD.2 group will exhibit a more positive trajectory in physical and mental health status, functional status, cognitive status and depressive symptoms over the course of a year than will the Medplanner Group.
H2: With respect to health status outcomes, the Medplanner Group will exhibit a more positive trajectory in physical and mental health status, functional status, cognitive status and depressive symptoms over the course of a year than will the Usual Care Group.
H3: The rate of hospitalization, hospital days and emergency department visits will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H4: The rate of hospitalization, hospital days and emergency department visits will be significantly lower for the Medplanner Group as compared to the Usual Care Group.
H5: The nursing home admission rate will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H6: The nursing home admission rate will be significantly lower for the Medplanner Group as compared to the Usual Care Group.
H7: The total cost of care will be significantly lower for the MD.2 Group as compared to the Medplanner Group.
H8: The total cost of care will be significantly lower for the Medplanner Group as compared to The Usual Care Group.
H9: There will be incremental savings in terms of costs per quality adjusted life year (QALY) gained in the MD.2 group compared with the Medplanner Group.
H10: There will be incremental savings in terms of costs per QALY gained in the Medplanner group compared with the Usual Care Group.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53201
- University of Wisconsin-Milwaukee
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 60 and older
- Medicare Primary Payer
- Impaired Medication Management ability as indicated by a score of 1 or higher on OASIS discharge assessment item M0780
- Impaired Cognitive Functioning but able to follow directions with prompting as indicated by a score of 1 or 2 on OASIS discharge assessment item M0560
- working telephone line
- Discharge from home health care
Exclusion Criteria:
- Not English speaking
- Terminal diagnosis or hospice care
- Use of other device for medications
- Medicare via managed care
- Use of private home care agency for medication management
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Machine and NCC
Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
|
MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition.
Additional visits made as needed.
Care is coordinated with other providers such as the primary care physician and pharmacist.
|
|
Sperimentale: Medplanner and NCC
Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
|
Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition.
Additional visits made as needed.
Care is coordinated with other providers such as the primary care physician and pharmacist.
|
|
Nessun intervento: Usual Care Group
Admitted post home health care with no intervention.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Geriatric Depression Scale
Lasso di tempo: 12 months
|
The Geriatric Depression Scale (GDS) was developed to identify depression in older adults.
The original GDS was 30 questions, however, fifteen- and five-question versions also exist.
When tested on the oldest old in the community, the 15-item scale was demonstrated to have favorable reliability and validity results.
Impaired cognitive function (MMSE < 28) reduced the tool's specificity, but sensitivity was not affected by lower MMSE scores.
The tool is scored into depression categories of "none/mild", "moderate" and "major".
|
12 months
|
|
Physical Performance Test (PPT)
Lasso di tempo: 12 months
|
This functional status test has demonstrated reliability and validity, is easy to administer, can be performed in a reasonable period of time, and imposes little burden on the individual being tested.
Even men and women with mild to moderate dementia are capable of understanding the test and performing activities reliably.
There are 7 items on the test that range in difficulty from very easy to perform (writing a sentence) to challenging (picking up a penny), thus encompassing a spectrum of physical capabilities.
|
12 months
|
|
SF-36 Health Survey
Lasso di tempo: 12 months
|
This tool is a widely used generic health status questionnaire measuring eight dimensions of health status: physical functioning, role limitations due to physical health problems, bodily pain, social functioning, general mental health, role limitations due to emotional problems, vitality, and general health perceptions.
In addition, the SF-36 can be transformed into a Health State Utility Index that allows for health improvements to be stated in terms of quality adjusted life years (QALYs) gained.
|
12 months
|
|
Mental Mental Status Exam (MMSE)
Lasso di tempo: 12 months
|
This 11-item measure screens for cognitive abilities in the domains of orientation, memory, attention, recall, language and visual/spatial orientation.
The MMSE may be a categorical or continuous-level variable.
When used as a categorical variable, the MMSE is broken down into 4 levels: (a) score range 24-30 is considered within normal limits (WNL), (b) score range of 18-23 is considered mild cognitive impairment, (c) score range of 12-17 is considered moderate cognitive impairment, and (d) a score range of 11 or less is considered to be severe cognitive impairment.
|
12 months
|
|
Hospitalization
Lasso di tempo: 12 month enrollment period
|
Medicare claims data will be the source of information for this measure.
|
12 month enrollment period
|
|
Hospital Days
Lasso di tempo: 12 Month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 Month Enrollment Period
|
|
Emergency Department Visits
Lasso di tempo: 12 month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 month Enrollment Period
|
|
Medicare Costs
Lasso di tempo: 12 Month Enrollment Period
|
Medicare claims data will be the source of information for this measure.
|
12 Month Enrollment Period
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Karen S Marek, PhD, Arizona State University
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 144PG09
- 5R01NR008911 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .